Key result
Beta-blockers show conflicting efficacy in HFpEF across published studies.
Why the study?
Evidence for beta-blocker therapy in HFpEF patients has shown conflicting findings with variably reported efficacy.
Does beta-blocker therapy improve outcomes in patients with heart failure with preserved ejection fraction?
Does beta-blocker therapy improve outcomes in patients with heart failure with preserved ejection fraction?
This review examines the conflicting evidence regarding the efficacy of beta-blocker therapy in patients with heart failure with preserved ejection fraction.
Conflicting evidence on beta-blockers in HFpEF warrants clinical caution; leaves open need for definitive RCTs.
Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a current cut-off of ≥50%. The evidence of beta-blocker therapy in HFpEF patients showed conflicting findings with variably reported efficacy. This review aims to examine the published studies on the use of beta blockers for the treatment of patients with HFpEF.
No takes yet. Share an insight, caveat, or question.
Kaddoura et al. (2023) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Beta-blocker therapy was evaluated. Beta-blocker therapy in patients with heart failure with preserved ejection fraction has shown conflicting findings with variably reported efficacy across published studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: